Pharma Journalist -

Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing…
Read More...

BioDuro, LLC, a leading drug discovery and development services organization, and neoX, a leading-edge artificial intelligence and biophysics focused biotech, announced a strategic…
Read More...

The University of Queensland’s COVID-19 vaccine has passed another important milestone, showing the ability to raise high levels of antibodies that can neutralise the virus in early…
Read More...

Gilead Sciences, Inc. announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in…
Read More...

Atreca, Inc. BeiGene, Ltd. and IGM Biosciences, Inc. announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) approved the company’s supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly…
Read More...

Catalent, Inc. announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of…
Read More...

London – On Tuesday, (12th May) CTS Virtual (https://arena-international.com/ctsvirtual/),  will host new key sessions on Clinical Trial Supply 2020 Trends, Stem-gene Clinical Trials…
Read More...

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced by Quotient Sciences and CytoAgents, Inc. The partnership will…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an additional recommended dosage of 400 mg every six…
Read More...